<DOC>
	<DOC>NCT01956812</DOC>
	<brief_summary>The is a double-blind, randomized phase 3 study of 90Y-clivatuzumab tetraxetan with low-dose gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer patients who have progressed on at least 2 prior therapies for metastatic cancer (1 of which was a gemcitabine-containing regimen).</brief_summary>
	<brief_title>Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan &amp; Gemcitabine vs Placebo &amp; Gemcitabine in Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid</mesh_term>
	<criteria>Histologically or cytologically confirmed adenocarcinoma of the pancreas Metastatic disease Received at least two prior systemic cytotoxic chemotherapy regimens for unresectable, locally advanced or metastatic disease. At least one of the prior systemic cytotoxic chemotherapy regimens for unresectable, locally advanced or metastatic disease must have contained gemcitabine and have met the following criteria: Completed at least one cycle of the treatment Received gemcitabine administered at a minimum dose of 800 mg/m2 per week in the first cycle of treatment Progressed while receiving this gemcitabine regimen or within 3 months of completing gemcitabine Progression was documented, Preferentially radiologically by tumor growth or new lesions, or by Clear symptomatic deterioration supported by at least two of the following clinical criteria: ≥ 10% worsening in KPS or ≥ 1 worsening in ECOG; increasing weakness or fatigue; progressive weight loss; new/worsening pain requiring increased pain medication; new/worsening jaundice, nausea, or vomiting; new/worsening ascites or pleural effusions; other physical or laboratory findings consistent with disease progression. KPS &gt;/= 70 Adequate bone marrow function Adequate hepatic function Adequate renal function CNS metastatic disease Bulky disease (any single mass &gt;10 cm). &gt;Grade 2 nausea or vomiting, and/or signs of intestinal obstruction. Prior external beam irradiation to a field that includes more than 30% of the red bone marrow. Patients with clinically significant severe cardiorespiratory disease. Please consult with the clinical trial site for the full detailed list of specific inclusion/exclusion criteria.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>clivatuzumab tetraxetan</keyword>
	<keyword>90Y-clivatuzumab tetraxetan</keyword>
	<keyword>IMMU-107</keyword>
</DOC>